Top-Rated StocksTop-RatedNASDAQ:IMVT Immunovant (IMVT) Stock Price, News & Analysis → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free IMVT Stock Alerts $25.39 -1.02 (-3.86%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$24.89▼$26.4850-Day Range$25.39▼$32.5252-Week Range$18.16▼$45.58Volume2.77 million shsAverage Volume1.05 million shsMarket Capitalization$3.71 billionP/E RatioN/ADividend YieldN/APrice Target$49.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Immunovant alerts: Email Address Immunovant MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside93.0% Upside$49.00 Price TargetShort InterestBearish15.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 26 Articles This WeekInsider TradingSelling Shares$2.94 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.80) to ($1.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.20 out of 5 starsMedical Sector616th out of 928 stocksBiological Products, Except Diagnostic Industry99th out of 153 stocks 4.5 Analyst's Opinion Consensus RatingImmunovant has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 17 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunovant has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunovant's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted15.25% of the float of Immunovant has been sold short.Short Interest Ratio / Days to CoverImmunovant has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Immunovant has recently increased by 3.68%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldImmunovant does not currently pay a dividend.Dividend GrowthImmunovant does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMVT. Previous Next 2.5 News and Social Media Coverage News SentimentImmunovant has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Immunovant this week, compared to 5 articles on an average week.Search Interest25 people have searched for IMVT on MarketBeat in the last 30 days. This is an increase of 32% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Immunovant to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunovant insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,936,889.00 in company stock.Percentage Held by InsidersOnly 4.80% of the stock of Immunovant is held by insiders.Percentage Held by Institutions47.08% of the stock of Immunovant is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunovant's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Immunovant are expected to decrease in the coming year, from ($1.80) to ($1.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunovant is -13.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunovant is -13.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunovant has a P/B Ratio of 6.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immunovant's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyKiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but Biden does not care.I have uncovered a bombshell that changes everything… and threatens everything. About Immunovant Stock (NASDAQ:IMVT)Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Read More IMVT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMVT Stock News HeadlinesMay 25, 2024 | insidertrades.comInsider Selling: Immunovant, Inc. (NASDAQ:IMVT) Insider Sells 3,247 Shares of StockJune 2 at 3:58 AM | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) Given Consensus Recommendation of "Buy" by AnalystsJune 2 at 2:46 AM | americanbankingnews.comImmunovant, Inc. (NASDAQ:IMVT) to Post Q1 2026 Earnings of ($0.62) Per Share, HC Wainwright ForecastsJune 2 at 2:46 AM | americanbankingnews.comImmunovant, Inc. to Post FY2025 Earnings of ($1.73) Per Share, Lifesci Capital Forecasts (NASDAQ:IMVT)June 1 at 5:26 AM | americanbankingnews.comImmunovant (NASDAQ:IMVT) Rating Reiterated by Cantor FitzgeraldJune 1 at 4:32 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Immunovant (NASDAQ:IMVT)May 31 at 7:34 AM | americanbankingnews.comImmunovant (NASDAQ:IMVT) Announces Quarterly Earnings ResultsMay 31 at 1:58 AM | americanbankingnews.comRevolution Medicines (NASDAQ:RVMD) vs. Immunovant (NASDAQ:IMVT) Head to Head ContrastMay 31 at 1:24 AM | americanbankingnews.comImmunovant (NASDAQ:IMVT) Shares Gap Down After Earnings MissMay 29, 2024 | globenewswire.comImmunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024May 29, 2024 | markets.businessinsider.comBiohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage StudyMay 29, 2024 | investing.comImmunovant (IMVT) Earnings Dates & ReportsMay 27, 2024 | americanbankingnews.comJulia G. Butchko Sells 3,247 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockMay 27, 2024 | americanbankingnews.comInsider Selling: Immunovant, Inc. (NASDAQ:IMVT) CEO Sells $479,232.95 in StockMay 26, 2024 | americanbankingnews.comEva Renee Barnett Sells 4,042 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockMay 19, 2024 | morningstar.comImmunovant Inc IMVTMay 7, 2024 | seekingalpha.comargenx: Innovation Over Losses In Autoimmune ArenaMay 7, 2024 | finance.yahoo.comZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and LigandApril 28, 2024 | investing.comImmunovant CTO sells shares worth over $209k to cover taxesApril 24, 2024 | finance.yahoo.comShould You Hold Immunovant (IMVT)?April 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immunovant on Strong Drug Development Prospects and Efficacy ConfidenceApril 20, 2024 | investing.comImmunovant CFO sells shares worth over $350kApril 16, 2024 | finance.yahoo.comImmunovant, Inc. (IMVT) Stock Historical Prices & Data - Yahoo FinanceApril 15, 2024 | nasdaq.comImmunovant is Now Oversold (IMVT)April 12, 2024 | investing.comImmunovant CEO sells over $149,000 in company stockSee More Headlines Receive IMVT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/29/2024Today6/02/2024Next Earnings (Estimated)8/08/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IMVT CUSIPN/A CIK1764013 Webwww.immunovant.com Phone917-580-3099FaxN/AEmployees164Year FoundedN/APrice Target and Rating Average Stock Price Target$49.00 High Stock Price Target$57.00 Low Stock Price Target$34.00 Potential Upside/Downside+93.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-210,960,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.40% Return on Assets-48.85% Debt Debt-to-Equity RatioN/A Current Ratio13.70 Quick Ratio22.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.23 per share Price / Book6.00Miscellaneous Outstanding Shares146,050,000Free Float138,319,000Market Cap$3.71 billion OptionableOptionable Beta0.70 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Frank M. Torti M.B.A. (Age 45)M.D., Executive Chairperson of the Board Comp: $92.5kDr. Peter Salzmann M.B.A. (Age 56)M.D., CEO & Director Comp: $1.02MMs. Eva Renee Barnett M.B.A. (Age 43)Chief Financial Officer Comp: $871.07kDr. William L. Macias M.D. (Age 65)Ph.D., Chief Medical Officer Comp: $719.88kDr. Jay S. Stout Ph.D. (Age 60)Chief Technology Officer Dr. Chau Cheng M.B.A.Ph.D., Vice President of Investor RelationsMr. Mark S. Levine (Age 51)Chief Legal Officer & Corporate Secretary Ms. Lauren Schrier M.B.A.Vice President of MarketingMs. Christine BlodgettVice President of Human ResourcesDr. Julia G. Butchko Ph.D. (Age 53)Chief Development Officer Comp: $531kMore ExecutivesKey CompetitorsVivint Smart HomeNYSE:VVNTUtz BrandsNYSE:UTZAdvantage SolutionsNASDAQ:ADVChurchill Capital Corp IVNYSE:CCIVMultiPlanNYSE:MPLNView All CompetitorsInsiders & InstitutionsPeter SalzmannSold 16,163 sharesTotal: $479,232.95 ($29.65/share)Julia G ButchkoSold 3,247 sharesTotal: $96,273.55 ($29.65/share)Eva Renee BarnettSold 4,042 sharesTotal: $119,845.30 ($29.65/share)Ikarian Capital LLCSold 92,469 shares on 5/17/2024Ownership: 0.191%Castleark Management LLCBought 80,440 shares on 5/17/2024Ownership: 0.055%View All Insider TransactionsView All Institutional Transactions IMVT Stock Analysis - Frequently Asked Questions Should I buy or sell Immunovant stock right now? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMVT shares. View IMVT analyst ratings or view top-rated stocks. What is Immunovant's stock price target for 2024? 17 brokerages have issued 12-month target prices for Immunovant's shares. Their IMVT share price targets range from $34.00 to $57.00. On average, they predict the company's share price to reach $49.00 in the next year. This suggests a possible upside of 93.0% from the stock's current price. View analysts price targets for IMVT or view top-rated stocks among Wall Street analysts. How have IMVT shares performed in 2024? Immunovant's stock was trading at $42.13 at the beginning of the year. Since then, IMVT shares have decreased by 39.7% and is now trading at $25.39. View the best growth stocks for 2024 here. When is Immunovant's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our IMVT earnings forecast. How were Immunovant's earnings last quarter? Immunovant, Inc. (NASDAQ:IMVT) posted its quarterly earnings results on Wednesday, May, 29th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.08. During the same period last year, the firm posted ($0.46) EPS. What ETFs hold Immunovant's stock? ETFs with the largest weight of Immunovant (NASDAQ:IMVT) stock in their portfolio include SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB). What other stocks do shareholders of Immunovant own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ). Who are Immunovant's major shareholders? Immunovant's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.46%), Alpine Global Management LLC (1.30%), Price T Rowe Associates Inc. MD (1.28%), Redmile Group LLC (0.67%), Lord Abbett & CO. LLC (0.43%) and Principal Financial Group Inc. (0.40%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Jay S Stout, Julia G Butchko, Mark S Levine, Michael Geffner, Peter Salzmann, Sciences Ltd Roivant and William L Macias. View institutional ownership trends. How do I buy shares of Immunovant? Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMVT) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.